|
Why you need to go:
The Experimental Man Project: The impact of biomarkers and personalized medicine on patients and consumersDavid Ewing Duncan, Director, Center for Life Science Policy, UC Berkeley
An institute without walls to further collaborations in translational medicine for pediatric cancer Beth Anne BaberCo‐Founder, CEO, and President, The Nicholas Conor Institute for Pediatric Cancer Research
The Coming Age of TheranosticsAmit Agarwal, Partner, Scientia Advisors Changing decision‐making in life sciences & personalized medicine: Applied Semantic Knowledgebases (ASK ®) at work! Erich A. Gombocz, Vice President, Chief Scientific Officer, IO Informatics
Personalized and Painless: A Non-invasive Disease Detection and Companion Diagnostic Tool George Schwartz, CEO, DermTech, andWilliam Wachsman, Associate Professor of Medicine,
UC San Diego
Introducing the Genome Commons Steven Brenner Principal Investigator of the Genome Commons Associate Professor at the University of California, Berkeley
Frequency of somatic mutations in human tumors classified by embryonic origin of tissues: identification of developmental lineage‐specific oncogenes and tumor suppressors Adam Pavlicek, Senior Principal Scientist in Computational Biology, Pfizer
Looking for cancer‐causing genes‐‐tumor vs. host? David W. Moskowitz, MD, Chairman, Chief Executive Officer and Chief Medical Officer, GenoMed
Point-of-care Personalized Medicine Ferran Prat, VP of Oncology and VP of Women’s Health at Inverness Medical Innovations
|
Email
Facebook
Twitter
LinkedIn
MySpace
Digg
del.icio.us
Reddit